Search

Syndax Pharmaceuticals Inc

Suletud

SektorTervishoid

16.88 -0.47

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.37

Max

17.28

Põhinäitajad

By Trading Economics

Sissetulek

-6.7M

-49M

Müük

7.9M

73M

Aktsiakasum

-0.55

Kasumimarginaal

-67.817

Töötajad

298

EBITDA

-5.9M

-37M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+119.22% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

2. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-125M

1.6B

Eelmine avamishind

17.35

Eelmine sulgemishind

16.88

Uudiste sentiment

By Acuity

77%

23%

302 / 340 Pingereas Healthcare

Syndax Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2026, 23:20 UTC

Syndax Pharmaceuticals Inc gained modestly in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

6. okt 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, hitting a low of over 5% earlier, and remain below the 20-day moving average.

2. okt 2026, 19:15 UTC

Syndax Pharmaceuticals Inc shares fell sharply, facing significant downward pressure and trading notably below its 20-day moving average amid broader biotechnology sector weakness.

1. okt 2026, 20:07 UTC

Social Media

Shares of Syndax Pharmaceuticals fell despite positive analyst ratings from H.C. Wainwright and Jefferies, remaining below the 20-day moving average.

30. sept 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is experiencing gains in Wednesday's trading session, rebounding significantly after an early dip and achieving a notable cumulative return since Tuesday.

29. sept 2026, 23:30 UTC

Syndax Pharmaceuticals Inc is rising in after-market trading, advancing from a low point post-market close and currently near the midpoint of its one-month trading range.

28. sept 2026, 19:16 UTC

News

Syndax Pharmaceuticals Inc. shares fell, remaining below the 20-day moving average despite being rated a "Strong Buy" following FDA approval for Revuforj.

25. sept 2026, 19:46 UTC

News
Social Media

Syndax Pharmaceuticals reaffirms over $2 billion in U.S. peak sales for Revuforj after SAVE trial results show an 88% overall response rate, driving shares higher.

24. sept 2026, 20:12 UTC

Syndax Pharmaceuticals Inc is trading higher in after-market hours, maintaining a steady position since Thursday's close, despite being below its 20-day moving average.

23. sept 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, reaching their lowest point around midday and remaining below the 20-day moving average after a significant decline from Tuesday's close.

22. sept 2026, 19:45 UTC

Syndax Pharmaceuticals Inc is trading modestly higher, though the price remains below its 20-day moving average and near the lower end of its one-month range.

21. sept 2026, 21:11 UTC

Syndax Pharmaceuticals Inc is advancing in after-market trading, reflecting notable upward movement since Monday's close, despite remaining below its 20-day moving average.

17. sept 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is trading higher, having seen a steady increase, despite being below its 20-day moving average and near the lower end of its one-month range.

16. sept 2026, 20:06 UTC

Macro Event

Syndax Pharmaceuticals Inc shares fell sharply, driven by heightened volatility in the healthcare sector following the Federal Reserve's recent 25 basis point interest rate hike.

15. sept 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

11. sept 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

10. sept 2026, 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

8. sept 2026, 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2. sept 2026, 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

1. sept 2026, 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

25. aug 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24. aug 2026, 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21. aug 2026, 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20. aug 2026, 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19. aug 2026, 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18. aug 2026, 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17. aug 2026, 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14. aug 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12. aug 2026, 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11. aug 2026, 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

Võrdlus sarnastega

Hinnamuutus

Syndax Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

119.22% tõus

12 kuu keskmine prognoos

Keskmine 37.333 USD  119.22%

Kõrge 57 USD

Madal 26 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Syndax Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

302 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.